Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-0523-L001
- Development stage
- Phase 1
- Lead developer
- Shanghai Jiao Tong University School of Medicine
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Injection
01
Overview
mRNA-0523-L001 is an individualized mRNA neoantigen vaccine designed to treat advanced endocrine tumors. The vaccine is personalized for each patient, encoding tumor-specific neoantigens identified from the patient's own tumor. It is delivered using lipid nanoparticles via injection. The vaccine aims to stimulate the patient's immune system to recognize and attack cancer cells expressing these specific neoantigens.
- Other names
- Individualized mRNA neoantigen vaccine
02
Targets
γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on mRNA-0523-L001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-0523-L001.